ERA Congress is the annual meeting of the European Renal Association (ERA).
Travere at ERA
The theme of the ERA 2025 Congress was “Game Changers in Nephrology.” Travere Therapeutics was excited to participate in the event and engage with renal healthcare professionals. We look forward to seeing you next year.
Program
Kidney Outcomes and the Effect of Proteinuria in Alport Syndrome: A Longitudinal Analysis Using Data From the National Registry of Rare Kidney Diseases (RaDaR)
Speakers: Katie Wong, David Pitcher, Dane Rogers, Sherry Masoud, Sascha Van Boemmel-Wegmann, Klaus Francke, Julie Lin, Shiguang Liu, Hannah Russell, Susie Gear, Alex Mercer, Bruce Hendry, A. Neil Turner, Daniel P. Gale
Type: Presentation
Meet a Travere MSL
Our Medical Science Liaisons (MSLs) are available to answer questions and provide support on Travere products.
Schedule a meetingPopulation Modelling Depicts the Mutational Burden of NPHS2 (podocin) Nephropathy and Reveals an Undiagnosed Later Onset Genetic Cohort
Speakers: Wen Ding, Karen Malone, Dinah Clark, Radko Komers, Pille Harrison, Fredrik Erlandsson, Moin Saleem
Type: Poster
Sparsentan Reversibly Decreases Mesangial IgA Deposition in gddY Mice: A Possible Role for Mesangial-Cell-Surface Autoantigen Expression
Speakers: Kazuaki Mori, Yoshihito Nihei, Celia Jenkinson, Bruce Hendry, Hitoshi Suzuki, Yusuke Suzuki
Type: Poster
Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial
Speakers: Jürgen Floege, Dana V. Rizk, Priscila Preciado, Brad Rovin, Stephanie Moody, Rob Geletka, Alex Mercer, Bruce Hendry, Radko Komers, Vladimir Tesar
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
Speakers: Isabelle M. Ayoub, Sydney Tang, Laura Kooienga, Priscila Preciado, David Lee, Radko Komers, Bruce Hendry, Alex Mercer, Stephanie Moody, Brad Rovin
Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX
Speakers: Vladimir Tesar, Hernan Trimarchi, James Tumlin, Laura Kooienga, Radko Komers, Jula Inrig, Edward Murphy, Eva Rodríguez García
MA-DS-25-0003 | May 2025